Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation
Status:
Completed
Trial end date:
2018-11-26
Target enrollment:
Participant gender:
Summary
In contrast with bisphosphonates,discontinuation of denosumab results in gradual loss of bone
mineral density gains. The investigators aim to evaluate whether in patients treated with
denosumab, a single zoledronic acid infusion would prevent the anticipated bone loss.
Phase:
Phase 4
Details
Lead Sponsor:
424 General Military Hospital
Collaborators:
251 Hellenic Air Force & VA General Hospital Leiden University Medical Center